Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

We are upgrading to Microsoft (MSFT) stock 'Buy' on as cloud, AI demand, margin expansion, and reduced Capex fuel growth.